Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1

B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality

(2015) R. G. Veenstra et al.   BLOOD

A scaling aneurysm model-based approach to assessing the role of flow pattern and energy loss in aneurysm rupture prediction

(2015) Yunling Long et al.   Journal of Translational Medicine

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

(2015) Kim C. Ohaegbulam et al.   TRENDS IN MOLECULAR MEDICINE

Tryptophan-Degrading Enzymes in Tumoral Immune Resistance

(2015) Nicolas van Baren et al.   Frontiers in Immunology

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal

(2015) Stefanie N. Linch et al.   Frontiers in Oncology

Abstract LB-193: Phase I study of safety, tolerability, pharmacokinetics, and pharmacodynamics of AMP-224 (B7-DC Fc fusion protein) in a regimen containing cyclophosphamide (CTX) in patients with advanced solid tumors.

(2014) Patricia M. LoRusso et al.   CANCER RESEARCH

VISTA Is an Immune Checkpoint Molecule for Human T Cells

(2014) J. L. Lines et al.   CANCER RESEARCH

VISTA Regulates the Development of Protective Antitumor Immunity

(2014) I. Le Mercier et al.   CANCER RESEARCH

Emerging Immunologic Biomarkers: Setting the (TNM-Immune) Stage

(2014) J. M. Taube   CLINICAL CANCER RESEARCH

Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein

(2014) M. Janakiram et al.   CLINICAL CANCER RESEARCH

RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance

(2014) Yanping Xiao et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

(2014) Sven de Vos et al.   Journal of Hematology & Oncology

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs

(2014) Lei Lu et al.   Journal of Translational Medicine

MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial

(2014) Emanuela Romano et al.   Journal of Translational Medicine

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

Structure and Cancer Immunotherapy of the B7 Family Member B7x

(2014) Hyungjun Jeon et al.   Cell Reports

Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues

(2014) I. Theate et al.   Cancer Immunology Research

Trial Watch

(2014) Fernando Aranda et al.   OncoImmunology

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

(2014) David A Schaer et al.   Journal for ImmunoTherapy of Cancer

Novel antibodies targeting immune regulatory checkpoints for cancer therapy

(2013) Chern Siang Lee et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients

(2013) B. D. Curti et al.   CANCER RESEARCH

Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder

(2013) E. Xylinas et al.   EJSO

Programmed death 1 and B and T lymphocyte attenuator immunoreceptors and their association with malignant T-lymphoproliferative disorders: brief review

(2013) Stamatis Karakatsanis et al.   HEMATOLOGICAL ONCOLOGY

Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity

(2013) Christine Pasero et al.   IMMUNOLOGY LETTERS

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

(2013) Jason R Westin et al.   LANCET ONCOLOGY

Advances in targeting cell surface signalling molecules for immune modulation

(2013) Sheng Yao et al.   NATURE REVIEWS DRUG DISCOVERY

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function

(2013) R. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

B7x and myeloid-derived suppressor cells in the tumor microenvironment

(2013) Hyungjun Jeon et al.   OncoImmunology

BTLA, a key regulator of Vγ9Vδ2 T-cell proliferation

(2013) Julie Gertner-Dardenne et al.   OncoImmunology

A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors

(2013) Stephen Ansell et al.   Journal for ImmunoTherapy of Cancer

A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma

(2012) William Bensinger et al.   BRITISH JOURNAL OF HAEMATOLOGY

Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia

(2012) L. A. Vitale et al.   CLINICAL CANCER RESEARCH

Modulation of GITR for cancer immunotherapy

(2012) David A Schaer et al.   CURRENT OPINION IN IMMUNOLOGY

Design of CD40 Agonists and Their Use in Growing B Cells for Cancer Immunotherapy

(2012) Richard S. Kornbluth et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma

(2012) Andrea Wang-Gillam et al.   INVESTIGATIONAL NEW DRUGS

B7x in the Periphery Abrogates Pancreas-Specific Damage Mediated by Self-reactive CD8 T Cells

(2012) J. S. Lee et al.   JOURNAL OF IMMUNOLOGY

Tissue-Expressed B7x Affects the Immune Response to and Outcome of Lethal Pulmonary Infection

(2012) K. A. Hofmeyer et al.   JOURNAL OF IMMUNOLOGY

B and T Lymphocyte Attenuator Mediates Inhibition of Tumor-Reactive CD8+ T Cells in Patients After Allogeneic Stem Cell Transplantation

(2012) W. Hobo et al.   JOURNAL OF IMMUNOLOGY

Immunotherapy of Cancer with 4-1BB

(2012) D. S. Vinay et al.   MOLECULAR CANCER THERAPEUTICS

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Agonist Anti-CD137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes

(2011) A. Palazon et al.   CANCER RESEARCH

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives

(2011) J. Godin-Ethier et al.   CLINICAL CANCER RESEARCH

Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms

(2011) Mikayel Mkrtichyan et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells

(2011) Scott K. Pruitt et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion

(2011) Kimberly A. Hofmeyer et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Tissue-specific expression of B7x protects from CD4 T cell–mediated autoimmunity

(2011) Joyce Wei et al.   JOURNAL OF EXPERIMENTAL MEDICINE

VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses

(2011) Li Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

6thAnnual European Antibody Congress 2010

(2011) Alain Beck et al.   mAbs

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Emerging Tim-3 functions in antimicrobial and tumor immunity

(2011) Kaori Sakuishi et al.   TRENDS IN IMMUNOLOGY

B7–H3 Ligand Expression by Primary Breast Cancer and Associated With Regional Nodal Metastasis

(2010) Takaaki Arigami et al.   ANNALS OF SURGERY

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

(2010) J.-J. Park et al.   BLOOD

CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells

(2010) H. Narazaki et al.   BLOOD

Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer

(2010) Jingting Jiang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The PD-1 pathway in tolerance and autoimmunity

(2010) Loise M. Francisco et al.   IMMUNOLOGICAL REVIEWS

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

(2010) Laurent Derré et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of CD27/CD70 pathway of activation in immunity and tolerance

(2010) Julie Denoeud et al.   JOURNAL OF LEUKOCYTE BIOLOGY

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

(2010) Chrystelle Brignone et al.   Journal of Translational Medicine

Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas

(2010) Xingxing Zang et al.   MODERN PATHOLOGY

Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors

(2010) H. K. Koblish et al.   MOLECULAR CANCER THERAPEUTICS

Programmed death-1–induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection

(2010) Elias A Said et al.   NATURE MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies

(2010) Paolo A. Ascierto et al.   SEMINARS IN ONCOLOGY

High Expression of the Inhibitory Receptor BTLA in T-Follicular Helper Cells and in B-Cell Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia

(2009) Hasni M’Hidi et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma

(2009) C. Brignone et al.   CLINICAL CANCER RESEARCH

The significance of OX40 and OX40L to T-cell biology and immune disease

(2009) Michael Croft et al.   IMMUNOLOGICAL REVIEWS

Molecular mechanism and function of CD40/CD40L engagement in the immune system

(2009) Raul Elgueta et al.   IMMUNOLOGICAL REVIEWS

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

(2008) T. Azuma et al.   BLOOD

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

(2008) Silvia Piconese et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The contrasting role of B7-H3

(2008) K. A. Hofmeyer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA